Zobraziť v EDS

The safety of paternal and maternal use of 5‐aminosalicylic acid during conception and pregnancy: a nationwide cohort study: A nationwide cohort study

Uložené v:
Podrobná bibliografia
Názov: The safety of paternal and maternal use of 5‐aminosalicylic acid during conception and pregnancy: a nationwide cohort study: A nationwide cohort study
Autori: Bente Mertz Nørgård, Sonia Friedman, Jens Kjeldsen, Jan Nielsen
Zdroj: Aliment Pharmacol Ther
Informácie o vydavateľovi: Wiley, 2022.
Rok vydania: 2022
Predmety: Male, 0301 basic medicine, Ulcerative, Cohort Studies, Fathers, 03 medical and health sciences, Crohn Disease, Pregnancy, Paternal Exposure/adverse effects, Humans, Child, Mesalamine, Paternal Use of 5‐asa during Conception and Pregnancy, 0303 health sciences, Mesalamine/adverse effects, Infant, Newborn, Infant, Colitis, Newborn, 3. Good health, Crohn Disease/drug therapy, Infant, Small for Gestational Age, Paternal Exposure, Small for Gestational Age, Colitis, Ulcerative, Female
Popis: SummaryBackgroundData on the safety of paternal use of 5‐aminosalicylic acid (5‐ASA) prior to conception are lacking, and the safety of maternal use of 5‐ASA during pregnancy has not been examined in nationwide data.AimsTo examine offspring outcomes after paternal pre‐conception use of 5‐ASA, and after maternal use during pregnancyMethodsThis nationwide cohort study was based on Danish health registries. The study population included live born singletons of patients with ulcerative colitis (UC) or Crohn's disease (CD). Paternal exposure included 2168 children fathered by men treated with 5‐ASA, and 7732 unexposed. Maternal exposure included 3618 children exposed in utero to 5‐ASA, and 7128 unexposed. The outcomes were pre‐term birth, small for gestational age (SGA), low Apgar score and major congenital abnormalities (CAs) according to EUROCAT guidelines.ResultsThe vast majority of fathers and mothers used mesalazine. In children fathered by men with UC using 5‐ASA, we found no increased risk of pre‐term birth, SGA or low Apgar score. The hazard ratio (HR) of CAs was 1.30 (95% CI 0.92–1.85). In children of fathers with CD, the odds ratio (OR) of SGA was 1.52 (95% CI 0.65–3.55). After maternal 5‐ASA exposure, the OR of SGA in children of women with UC was 1.46 (95% CI: 0.93–2.30); for CAs in children of women with CD, HR was 1.44 (95% CI 0.84–2.47).ConclusionsPaternal and maternal use of 5‐ASA was safe across offspring outcomes; none of the findings reached statistical significance. The safety of 5‐ASA formulations that are used infrequently cannot be settled here.
Druh dokumentu: Article
Other literature type
Jazyk: English
ISSN: 1365-2036
0269-2813
DOI: 10.1111/apt.17189
Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/36031741
https://portal.findresearcher.sdu.dk/da/publications/f97e413b-31cb-4ca9-883d-d21dcb55c280
https://doi.org/10.1111/apt.17189
Rights: CC BY NC
Prístupové číslo: edsair.doi.dedup.....5efe4743b610688e01f7081b6f045bf7
Databáza: OpenAIRE
Popis
Abstrakt:SummaryBackgroundData on the safety of paternal use of 5‐aminosalicylic acid (5‐ASA) prior to conception are lacking, and the safety of maternal use of 5‐ASA during pregnancy has not been examined in nationwide data.AimsTo examine offspring outcomes after paternal pre‐conception use of 5‐ASA, and after maternal use during pregnancyMethodsThis nationwide cohort study was based on Danish health registries. The study population included live born singletons of patients with ulcerative colitis (UC) or Crohn's disease (CD). Paternal exposure included 2168 children fathered by men treated with 5‐ASA, and 7732 unexposed. Maternal exposure included 3618 children exposed in utero to 5‐ASA, and 7128 unexposed. The outcomes were pre‐term birth, small for gestational age (SGA), low Apgar score and major congenital abnormalities (CAs) according to EUROCAT guidelines.ResultsThe vast majority of fathers and mothers used mesalazine. In children fathered by men with UC using 5‐ASA, we found no increased risk of pre‐term birth, SGA or low Apgar score. The hazard ratio (HR) of CAs was 1.30 (95% CI 0.92–1.85). In children of fathers with CD, the odds ratio (OR) of SGA was 1.52 (95% CI 0.65–3.55). After maternal 5‐ASA exposure, the OR of SGA in children of women with UC was 1.46 (95% CI: 0.93–2.30); for CAs in children of women with CD, HR was 1.44 (95% CI 0.84–2.47).ConclusionsPaternal and maternal use of 5‐ASA was safe across offspring outcomes; none of the findings reached statistical significance. The safety of 5‐ASA formulations that are used infrequently cannot be settled here.
ISSN:13652036
02692813
DOI:10.1111/apt.17189